Daniel Pichl
Net Worth

Last updated:

What is Daniel Pichl net worth?

The estimated net worth of Mr. Daniel Pichl is at least $5,776,601 as of 16 Feb 2024. He owns shares worth $2,124,060 as insider, has earned $1,938,501 from insider trading and has received compensation worth at least $1,714,040 in SpringWorks Therapeutics, Inc..

What is the salary of Daniel Pichl?

Mr. Daniel Pichl salary is $428,510 per year as Chief People Officer in SpringWorks Therapeutics, Inc..

How old is Daniel Pichl?

Mr. Daniel Pichl is 42 years old, born in 1983.

What stocks does Daniel Pichl currently own?

As insider, Mr. Daniel Pichl owns shares in one company:

Company Title Shares Price per share Total value
SpringWorks Therapeutics, Inc. (SWTX) Chief People Officer 45,212 $46.98 $2,124,060

What does SpringWorks Therapeutics, Inc. do?

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.

Daniel Pichl insider trading

SpringWorks Therapeutics, Inc.

Mr. Daniel Pichl has made 6 insider trades between 2021-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 16,250 units of SWTX stock on 2 Feb 2024. As of 16 Feb 2024 he still owns at least 45,212 units of SWTX stock.

Transaction Date Security Shares Price per share Total value Source
Option
Stock Option (Right to Buy) 15,000 $27.64 $414,600
Option
Common Stock 15,000 $27.64 $414,600
Sale
Common Stock 15,000 $50.1 $751,545
Sale
Common Stock 9,266 $43.81 $405,943
Sale
Common Stock 14,175 $44.31 $628,151
Sale
Common Stock 743 $46.44 $34,507
Option
Common Stock 16,250 $27.64 $449,150
Option
Stock Option (Right to Buy) 16,250 $27.64 $449,150
Sale
Common Stock 1,997 $45.95 $91,756
Sale
Common Stock 858 $31 $26,598
Option
Common Stock 2,320 $43.1 $99,992
Option
Stock Option (Right to Buy) 2,320 $43.1 $99,992

SpringWorks Therapeutics key executives

SpringWorks Therapeutics, Inc. executives and other stock owners filed with the SEC: